| Literature DB >> 29751507 |
Hellen C G Nabuco1,2, Crisieli M Tomeleri3,4, Paulo Sugihara Junior5, Rodrigo R Fernandes6, Edilaine F Cavalcante7, Melissa Antunes8, Alex S Ribeiro9, Denilson C Teixeira10,11, Analiza M Silva12, Luís B Sardinha13, Edilson S Cyrino14,15.
Abstract
Aging is associated with sarcopenia and dynapenia, with both processes contributing to functional dependence and mortality in older adults. Resistance training (RT) and increased protein intake are strategies that may contribute to health improvements in older adults. Therefore, the aim was to investigate the effects of whey protein (WP) supplementation consumed either immediately pre- or post-RT on skeletal muscle mass (SMM), muscular strength, and functional capacity in pre-conditioned older women. Seventy older women participated in this investigation and were randomly assigned to one of three groups: whey protein pre-RT and placebo post-RT (WP-PLA, n = 24), placebo pre-RT and whey protein post-RT (PLA-WP, n = 23), and placebo pre- and post-RT (PLA-PLA, n = 23). Each group ingested 35 g of WP or PLA. The RT program was carried out over 12 weeks (three times per week; 3 × 8⁻12 repetition maximum). Body composition, muscular strength, functional capacity, and dietary intake were assessed pre- and post-intervention. Two-way analysis of covariance (ANCOVA) for repeated measures, with baseline scores as covariates were used for data analysis. A time vs. group interaction (p < 0.05) was observed with WP-PLA and PLA-WP presenting greater increases compared with PLA-PLA for SMM (WP-PLA = 3.4%; PLA-WP = 4.2%; PLA-PLA = 2.0%), strength (WP-PLA = 8.1%; PLA-WP = 8.3%; PLA-PLA = 7.0%), and the 10-m walk test (WP-PLA = −10.8%; PLA-WP = −11.8%; PLA-PLA = −4.3%). Whey protein supplementation was effective in promoting increases in SMM, muscular strength, and functional capacity in pre-conditioned older women, regardless of supplementation timing. This trial was registered at ClinicalTrials.gov: NCT03247192.Entities:
Keywords: aging; hypertrophy; protein timing; strength training
Mesh:
Substances:
Year: 2018 PMID: 29751507 PMCID: PMC5986443 DOI: 10.3390/nu10050563
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow chart of the study.
Participant scores at baseline (pre) and after (post) the eight-week period (n = 70).
| Pre | Post | Δ% | ES |
| |
|---|---|---|---|---|---|
| Protein (g/kg/day) | 0.92 ± 0.28 | 0.94 ± 0.28 | 2.2 | 0.07 | 0.499 |
| CHO (g/kg/day) | 3.07 ± 1.0 | 3.15 ± 1.0 | 2.5 | 0.08 | 0.324 |
| Lipids (g/kg/day) | 0.70 ± 0.2 | 0.73 ± 0.2 | 4.5 | 0.14 | 0.233 |
| Energy (kcal/kg/day) | 22.3 ± 6.5 | 23.0 ± 6.5 | 3.1 | 0.10 | 0.178 |
| SMM (kg) | 16.6 ± 2.6 | 17.1 ± 2.7 | 3.1 | 0.19 | <0.001 |
| ULLST (kg) | 3.8 ± 0.6 | 4.0 ± 0.6 | 3.5 | 0.21 | <0.001 |
| LLLST (kg) | 11.5 ± 1.6 | 11.8 ± 1.7 | 2.5 | 0.17 | <0.001 |
| Chest press (kg) | 40.6 ± 8.5 | 44.8 ± 8.7 | 10.3 | 0.48 | <0.001 |
| Knee extension (kg) | 46.0 ± 11.3 | 52.6 ± 11.7 | 14.4 | 0.57 | <0.001 |
| Preacher curl (kg) | 18.4 ± 3.8 | 21.8 ± 3.7 | 18.3 | 0.89 | <0.001 |
| Total strength (kg) | 105.0 ± 19.7 | 119.3 ± 20.3 | 13.6 | 0.71 | <0.001 |
| 10 MW (s) | 7.8 ± 1.1 | 7.4 ± 0.9 | −4.8 | 0.37 | <0.001 |
| RSP (s) | 12.4 ± 2.2 | 11.8 ± 1.7 | −5.2 | 0.33 | <0.001 |
Paired t-test. Data are expressed as mean and standard deviation. CHO = carbohydrates; ES = effect size; SMM = skeletal muscle mass; ULLST = upper limb lean soft tissue; LLLST = lower limb lean soft tissue; 10 MW = 10-m walk test; RSP = rising from sitting position.
Habitual dietary intake of the older women measured at baseline, during, and after 12 weeks of intervention (n = 66).
| Whey Protein–Placebo ( | Placebo–Whey Protein ( | Placebo-Placebo ( | Interaction | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 6-Week | 12-Week | 0 | 6-Week | 12-Week | 0 | 6-Week | 12-Week | ||
| Intake excluding whey/control | ||||||||||
| Protein (g/kg/day) | 0.92 ± 0.20 | 0.95 ± 0.36 | 0.96 ± 0.19 | 0.94 ± 0.36 | 0.98 ± 0.52 | 0.98 ± 0.24 | 0.95 ± 0.27 | 0.96 ± 0.26 | 0.99 ± 0.25 | 0.914 |
| CHO (g/kg/day) | 3.1 ± 0.96 | 3.1 ± 0.91 | 3.0 ± 0.77 | 3.2 ± 1.12 | 3.1 ± 1.24 | 3.1 ± 1.13 | 3.1 ± 0.94 | 3.1 ± 0.84 | 3.1 ± 0.72 | 0.968 |
| Lipids (g/kg/day) | 0.77 ± 0.29 | 0.72 ± 0.27 | 0.69 ± 0.19 | 0.76 ± 0.30 | 0.72 ± 0.21 | 0.74 ± 0.32 | 0.67 ± 0.17 | 0.73 ± 0.14 | 0.75 ± 0.34 | 0.485 |
| Energy (kcal/kg/day) | 22.9 ± 6.29 | 23.1 ± 7.76 | 23.2 ± 6.28 | 22.4 ± 7.75 | 23.3 ± 7.76 | 23.3 ± 6.28 | 22.4 ± 5.90 | 23.2 ± 4.6 | 23.4 ± 6.3 | 0.810 |
| Intake including whey/control | ||||||||||
| Protein (g/kg/day) | 0.92 ± 0.20 | 1.38 ± 0.42 *,§ | 1.38 ± 0.26 *,§ | 0.94 ± 0.36 | 1.42 ± 0.57 *,§ | 1.49 ± 0.46 *,§ | 0.95 ± 0.27 | 0.98 ± 0.30 | 1.0 ± 0.25 | <0.001 |
| CHO (g/kg/day) | 3.1 ± 0.96 | 3.7 ± 0.93 * | 3.6 ± 0.85 *,§ | 3.2 ± 1.12 | 3.4 ± 1.5 § | 3.6 ± 1.2 *,§ | 3.1 ± 0.94 | 4.2 ± 1.0 * | 4.2 ± 0.90 * | <0.001 |
| Lipids (g/kg/day) | 0.77 ± 0.29 | 0.72 ± 0.27 | 0.70 ± 0.17 | 0.76 ± 0.30 | 0.70 ± 0.29 | 0.74 ± 0.31 | 0.67 ± 0.17 | 0.72 ± 0.14 | 0.75 ± 0.33 | 0.279 |
| Energy (kcal/kg/day) | 22.9 ± 6.29 | 26.6 ± 7.0 | 26.1 ± 5.6 * | 22.4 ± 7.75 | 25.3 ± 10.4 | 28.0 ± 6.7 * | 22.4 ± 5.90 | 27.2 ± 4.6 * | 27.8 ± 6.8 * | 0.435 |
Analysis of variance (ANOVA) two-way. Data are expressed as mean and standard deviation. ES = effect size; CHO = carbohydrates. * p < 0.05 vs. pre training; § p < 0.05 vs. placebo-placebo.
Body composition and muscular strength of the older women after the 12-week intervention period (n = 66).
| Whey Protein–Placebo ( | Placebo–Whey Protein ( | Placebo-Placebo ( | Interaction | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Δ% | ES | Pre | Post | Δ% | ES | Pre | Post | Δ% | ES | ||
| SMM (kg) | 17.7 ± 2.5 | 18.4 ± 2.4 *,§ | 3.4 ± 2.9 | 0.25 | 17.4 ± 3.2 | 18.2 ± 3.2 *,§ | 4.2 ± 2.3 | 0.23 | 16.2 ± 2.2 | 16.6 ± 2.2 * | 2.0 ± 2.1 | 0.14 | <0.001 |
| ULLST (kg) | 4.1 ± 0.47 | 4.2 ± 0.45 * | 3.4 ± 3.0 | 0.29 | 3.9 ± 0.54 | 4.1 ± 0.58 * | 5.9 ± 4.3 | 0.40 | 3.7 ± 0.53 | 3.9 ± 0.53 * | 4.1 ± 3.5 | 0.29 | 0.156 |
| LLLST (kg) | 11.8 ± 1.2 | 12.1 ± 1.1 *,§ | 3.2 ± 2.9 | 0.30 | 11.6 ± 1.4 | 12.0 ± 1.5 *,§ | 3.7 ± 2.2 | 0.30 | 11.3 ±1.4 | 11.4 ± 1.4 * | 1.1 ± 2.2 | 0.08 | <0.001 |
| CP (kg) | 46.0 ± 9.0 | 49.0 ± 10.0 *,§ | 5.6 ± 1.7 | 0.28 | 45.0 ± 9.0 | 48.0 ± 10.0 *,§ | 5.9 ± 1.6 | 0.28 | 43.0 ± 8.0 | 45.0 ± 8.0 * | 4.5 ± 1.2 | 0.24 | <0.05 |
| KE (kg) | 52.0 ± 11.0 | 56.0 ± 12.0 *,§ | 9.2 ± 2.5 | 0.39 | 55.0 ± 11.0 | 59.0 ± 12.0 *,§ | 8.8 ± 2.2 | 0.41 | 52.0 ± 13.0 | 56.0 ± 13.0 * | 7.5 ± 1.0 | 0.32 | <0.001 |
| PC (kg) | 23.0 ± 4.0 | 25.0 ± 4.0 * | 11.3 ± 5.7 | 0.59 | 22.0 ± 3.0 | 25.0 ± 4.0 * | 12.4 ± 6.6 | 0.75 | 21.0 ± 3.0 | 23.0 ± 4.0 * | 10.5 ± 5.3 | 0.63 | 0.376 |
| TS (kg) | 121.0 ± 20.0 | 131.0 ± 21.0 *,§ | 8.1 ± 1.6 | 0.48 | 122.0 ± 21.0 | 132.0 ± 22.0 *,§ | 8.3 ± 2.3 | 0.47 | 115.0 ± 21.0 | 124.0 ± 22.0 * | 7.0 ± 2.7 | 0.38 | <0.05 |
| Training load (kg) | 1735 ± 232 | 2505 ± 292 * | 45.3 ± 14.8 | 2.93 | 1698 ± 224 | 2429 ± 377 * | 43.6 ± 18.3 | 2.44 | 1630 ± 276 | 2367 ± 442 * | 44.7 ± 14.2 | 2.05 | 0.916 |
| 10 MW (s) | 7.5 ± 0.9 | 6.7 ± 0.9 *,§ | −10.8 ± 11.3 | 0.90 | 7.5 ± 1.0 | 6.6 ± 1.0 *,§ | −11.8 ± 8.6 | 0.89 | 7.3 ± 0.9 | 6.9 ± 0.7 * | −4.3 ± 8.4 | 0.41 | <0.05 |
| RSP (s) | 12.0 ± 1.6 | 10.8 ± 1.1 * | −10.0 ± 12.4 | 0.89 | 11.7 ± 1.5 | 10.5 ± 1.7 * | −10.1 ± 5.4 | 0.73 | 11.7 ± 1.8 | 11.0 ± 1.8 * | −5.7 ± 7.6 | 0.36 | 0.176 |
ANCOVA two-way. Data are expressed as mean and standard deviation. ES = effect size; SMM = skeletal muscle mass; ULLST = upper limb lean soft tissue; LLLST = lower limb lean soft tissue; CP = Chest press; KE = Knee extension; PC = Preacher curl; TS = total strength; 10 MW = 10-m walk test; RSP = rising from sitting position.* p < 0.05 vs. pre training; § p < 0.05 vs. placebo-placebo.
Figure 2Relative skeletal muscle mass changes from the first phase and the supplementation phase. During the first phase no supplementation was provided, data are presented separately to show that both groups demonstrated the same behavior during the pre-supplementation phase in the same training phase. § p < 0.05 vs. placebo-placebo.